Tag: cdmo market statistics

Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.

Biologics CDMO Market Set To Climb From $27.55 Billion In 2026 To $48.06 Billion By 2030

The biologics cdmo market size has seen rapid growth in recent years. It is forecast to expand from $24.15 billion in 2025 to $27.56 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 14.1%. The expansion observed historically is attributable to a rise in biologics research, progress in cell culture technologies, the increasing occurrence of chronic diseases, the development of biosimilar pipelines, and government assistance for biopharma manufacturing.

The biologics CDMO market is projected to experience swift expansion in the coming years. This market is set to reach $48.07 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 14.9%. Factors contributing to this growth during the projected timeframe include a significant increase in gene and cell therapy development, the integration of automation and robotics into CDMO operations, an expansion of worldwide biologics manufacturing capabilities, growing investment in precision medicine, and an increasing need for economical biologics. Key trends anticipated within this period encompass the broadening of biologics CDMO service offerings, an uptick in mammalian cell-based production, greater outsourcing of gene therapy manufacturing, the implementation of sophisticated bioprocessing methods, and a growing demand for biosimilars.

Get A Free Sample Report With In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=14056&type=smp&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Biologics CDMO Market Demand Drivers Opening New Revenue Streams

The increasing need for cell and genetic therapy is projected to drive the expansion of the biologic CDMO market. Cell and gene therapy represent advanced medical strategies that utilize living cells or genetic material to address the fundamental causes of diseases at the cellular or genetic level, providing potential remedies for conditions that are hard to manage or incurable through traditional pharmaceuticals. The demand for these therapies is on the rise due to their potential to offer novel treatments by directly targeting underlying genetic or cellular issues. Biologic CDMOs contribute expertise in handling living cells, viral vectors, and genetic materials, ensuring the safe and efficient production of cell and gene therapies. They also assist biopharmaceutical companies in navigating regulatory requirements and technical challenges, thereby facilitating their progression from research to clinical application. For instance, in March 2024, IQVIA Holdings Inc., a US-based provider of advanced analytics, technology solutions, and clinical research services for the life sciences and healthcare industries, reported that global spending on cell and gene therapies soared to $5.9 billion in 2023, representing a 38% increase from 2022. Therefore, the significant surge in demand for cell and genetic therapy is propelling the growth of the biologic CDMO market.

Biologics CDMO Market Segment Breakdown: Which Categories Lead On Revenue?

The biologics cdmo market covered in this report is segmented –

1) By Cell Type: Mammalian, Non-Mammalian

2) By Product Type: Biologics, Biosimilars

3) By Service Type: Drug Substance Manufacturing, Drug Product (Fill–Finish) Manufacturing, Process Development, Analytical & Quality Testing Services

Subsegments:

1) By Mammalian: Chinese Hamster Ovary (CHO) Cells, Human Embryonic Kidney (HEK) Cells, Other Mammalian Cells

2) By Non-Mammalian: Yeast Cells, Bacterial Cells, Insect Cells, Other Non-Mammalian Cells

Biologics CDMO Market Trends Powering Strategic Industry Growth

Leading companies in the biologics CDMO market are advancing technologically sophisticated solutions, such as novel cell lines, to boost the efficiency and capabilities of biopharmaceutical development and manufacturing. This technology generates therapeutic antibodies with enhanced potency, addressing obstacles in immunotherapy research and development. For instance, in November 2023, Lonza Group, a Switzerland-based manufacturing firm specializing in the pharmaceutical and biotechnology sectors, unveiled its GS Effex cell lines. These are engineered to produce antibodies that are 100% free of fucose, a sugar molecule, and exhibit increased potency without sacrificing other performance attributes. This development aids in overcoming immunotherapy research and development challenges tied to the requirement for more potent antibody therapeutics. It represents a stable, scalable, and productive cell line, offering a solution for therapeutic development from the discovery phase all the way through commercial manufacturing.

Biologics CDMO Market Leading Players And Competitive Positioning

Major companies operating in the biologics cdmo market are Lonza Group Ltd, Samsung Biologics Co Ltd, WuXi Biologics Cayman Inc, Catalent Inc, Thermo Fisher Scientific Inc, Boehringer Ingelheim International GmbH, Emergent BioSolutions Inc, Grifols SA, AbbVie Inc, Novartis AG, Sandoz International GmbH, Fujifilm Holdings Corporation, AGC Inc, JSR Corporation, Shenzhen Hepalink Pharmaceutical Co Ltd, Kemwell Biopharma Pvt Ltd, Bora Pharmaceuticals Co Ltd, Binex Co Ltd, 3P Biopharmaceuticals SLU, Cytovance Biologics

View The Full Biologics CDMO Market Report:

https://www.thebusinessresearchcompany.com/report/biologics-cdmo-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Biologics CDMO Market Geographic Analysis: Where Is Demand Rising Fastest?

North America was the largest region in the biologics CDMO market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biologics cdmo market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.

Biologics CDMO Market Value Analysis: What Growth Is Expected Over The Forecast Period?

The biologics CDMO market has experienced swift expansion in recent years, with projections indicating an increase from $24.15 billion in 2025 to $27.56 billion in 2026, reflecting a compound annual growth rate (CAGR) of 14.1%. This historical growth has been driven by factors including heightened biologics research, progress in cell culture techniques, a rising incidence of chronic illnesses, expansion of biosimilar development efforts, and governmental backing for biopharmaceutical production.

The biologics CDMO market is forecasted to experience substantial expansion over the coming years. Its value is projected to reach $48.07 billion by 2030, reflecting a compound annual growth rate (CAGR) of 14.9%. This anticipated growth during the forecast period is driven by a surge in the development of gene and cell therapies, the growing implementation of automation and robotics within CDMO operations, the increase in global manufacturing capabilities for biologics, heightened investment in precision medicine, and a rising need for cost-effective biologic solutions. Key developments expected in this period include the broadening of biologics CDMO offerings, a rise in mammalian cell-based production, greater outsourcing of gene therapy manufacturing, the adoption of cutting-edge bioprocessing methods, and an escalating demand for biosimilars.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=14056&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

#Biologics CDMO Market Growth Factors: Which Forces Are Supporting Market Expansion?

The growing need for cell and genetic therapies is expected to boost the biologic CDMO market moving forward. These treatment approaches use living cells or genetic material to target disease causes at a cellular or genetic level, offering hope for conditions that are hard to treat or incurable with standard drugs. Rising demand stems from their ability to provide novel solutions for diseases by tackling root genetic or cellular issues. Biologic CDMOs bring specialized skills in managing live cells, viral vectors, and genetic components, ensuring safe and effective production of these therapies while helping biopharma firms meet regulatory hurdles and technical obstacles, thus easing the shift from research to clinical use. For example, in March 2024, IQVIA Holdings Inc., a US-based firm offering advanced analytics, tech solutions, and clinical research services for life sciences and healthcare, reported that global spending on cell and gene therapies hit $5.9 billion in 2023, a 38% jump from 2022. Consequently, the rising demand for cell and gene therapy is fueling growth in the biologic CDMO market.

Biologics CDMO Market Segment Analysis: What Are The Major Market Categories?

The biologics cdmo market covered in this report is segmented –

1) By Cell Type: Mammalian, Non-Mammalian

2) By Product Type: Biologics, Biosimilars

3) By Service Type: Drug Substance Manufacturing, Drug Product (Fill–Finish) Manufacturing, Process Development, Analytical & Quality Testing Services

Subsegments:

1) By Mammalian: Chinese Hamster Ovary (CHO) Cells, Human Embryonic Kidney (HEK) Cells, Other Mammalian Cells

2) By Non-Mammalian: Yeast Cells, Bacterial Cells, Insect Cells, Other Non-Mammalian Cells

Biologics CDMO Market Industry Trends: What Changes Are Reshaping Demand?

Major players in the biologics contract development and manufacturing organization (CDMO) market are rolling out highly advanced technological solutions, including novel cell lines, aimed at boosting the efficiency and capabilities of biopharmaceutical development and production. This technology enables the creation of therapeutic antibodies with greater potency, addressing persistent challenges in immunotherapy research and development. For example, in November 2023, Lonza Group, a Swiss contract manufacturing firm focusing on the pharmaceutical and biotech sectors, introduced its GS Effex cell lines. These are specifically engineered to generate completely fucose-free antibodies, thereby enhancing their potency without sacrificing performance in other areas. This innovation helps meet the need for more effective antibody therapeutics in immunotherapy research. The cell line is stable, scalable, and productive, offering a complete solution for therapeutic development ranging from early discovery all the way to commercial-scale manufacturing.

Biologics CDMO Market Leading Companies Driving Competitive Growth

Major companies operating in the biologics cdmo market are Lonza Group Ltd, Samsung Biologics Co Ltd, WuXi Biologics Cayman Inc, Catalent Inc, Thermo Fisher Scientific Inc, Boehringer Ingelheim International GmbH, Emergent BioSolutions Inc, Grifols SA, AbbVie Inc, Novartis AG, Sandoz International GmbH, Fujifilm Holdings Corporation, AGC Inc, JSR Corporation, Shenzhen Hepalink Pharmaceutical Co Ltd, Kemwell Biopharma Pvt Ltd, Bora Pharmaceuticals Co Ltd, Binex Co Ltd, 3P Biopharmaceuticals SLU, Cytovance Biologics

Access The Complete Biologics CDMO Market Report:

https://www.thebusinessresearchcompany.com/report/biologics-cdmo-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Biologics CDMO Market Leading Geography: Which Region Generates The Most Revenue?

North America was the largest region in the biologics CDMO market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biologics cdmo market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

How Will The Market Size Of The Biologics CDMO Market Progress Through 2030?

The biologics cdmo market has experienced significant growth in recent years. Its value is expected to rise from $24.15 billion in 2025 to $27.56 billion in 2026, achieving a compound annual growth rate (CAGR) of 14.1%. Historically, this expansion has been driven by increased biologics research, advancements in cell culture technologies, a growing incidence of chronic diseases, the development of biosimilar pipelines, and government support for biopharma manufacturing.

The biologics CDMO market is projected for substantial expansion over the next few years. Its size is anticipated to reach $48.07 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 14.9%. This projected growth during the forecast period is attributable to several factors, including a surge in gene and cell therapy development, the adoption of automation and robotics in CDMO processes, an expansion of global biologics manufacturing capacity, increasing investment in precision medicine, and a rising demand for cost-effective biologics. Key trends expected within the forecast timeframe encompass the expansion of biologics CDMO services, growth in mammalian cell-based production, an increase in the outsourcing of gene therapy manufacturing, the adoption of advanced bioprocessing techniques, and a rising demand for biosimilars.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=14056&type=smp

What Market Drivers Are Helping Shape The Biologics CDMO Market Expansion?

The increasing need for cell and genetic therapy is anticipated to drive expansion in the biologic CDMO market. Cell and gene therapies represent groundbreaking medical strategies, employing living cells or genetic material to target the root causes of diseases at a cellular or genetic level. This offers promising treatments for conditions often challenging or impossible to cure with conventional drugs, leading to a growing demand for these therapies due to their potential to provide novel solutions by addressing fundamental genetic or cellular issues. Biologic CDMOs offer specialized knowledge in managing living cells, viral vectors, and genetic material. This enables the secure and effective manufacture of cell and gene therapies, supporting biopharmaceutical firms through regulatory complexities and technical hurdles, thus accelerating the transition from laboratory research to clinical implementation. A notable example is observed in March 2024, when IQVIA Holdings Inc., a US-based provider of advanced analytics, technology solutions, and clinical research services for the life sciences and healthcare industries, reported that global expenditures on cell and gene therapies reached $5.9 billion in 2023, marking a significant 38% increase from 2022. Consequently, this heightened demand for cell and genetic therapy is a key factor propelling the expansion of the biologic CDMO market.

What Key Segment Areas Are Included In The Biologics CDMO Market Assessment?

The biologics cdmo market covered in this report is segmented –

1) By Cell Type: Mammalian, Non-Mammalian

2) By Product Type: Biologics, Biosimilars

3) By Service Type: Drug Substance Manufacturing, Drug Product (Fill–Finish) Manufacturing, Process Development, Analytical & Quality Testing Services

Subsegments:

1) By Mammalian: Chinese Hamster Ovary (CHO) Cells, Human Embryonic Kidney (HEK) Cells, Other Mammalian Cells

2) By Non-Mammalian: Yeast Cells, Bacterial Cells, Insect Cells, Other Non-Mammalian Cells

Which Trends Are Affecting The Biologics CDMO Market Framework?

Leading companies within the biologics CDMO market are actively developing sophisticated technological solutions, such as innovative cell lines, to bolster the efficiency and capabilities of biopharmaceutical development and manufacturing. This technology is capable of producing therapeutic antibodies with significantly enhanced potency, thereby addressing crucial challenges in immunotherapy research and development. For instance, in November 2023, Lonza Group, a manufacturing company based in Switzerland specializing in the pharmaceutical and biotechnology sectors, unveiled GS Effex cell lines. These were specifically designed to yield antibodies that are 100% free of fucose, a sugar molecule, and demonstrate increased potency without compromising other performance attributes. This innovation helps to overcome immunotherapy research and development challenges related to the necessity for antibody therapeutics to boost their potency. It is a stable, scalable, and productive cell line that offers a comprehensive solution for therapeutic development, spanning from discovery-stage research through to commercial manufacturing.

Which Companies Form The Competitive Landscape Of The Biologics CDMO Market?

Major companies operating in the biologics cdmo market are Lonza Group Ltd, Samsung Biologics Co Ltd, WuXi Biologics Cayman Inc, Catalent Inc, Thermo Fisher Scientific Inc, Boehringer Ingelheim International GmbH, Emergent BioSolutions Inc, Grifols SA, AbbVie Inc, Novartis AG, Sandoz International GmbH, Fujifilm Holdings Corporation, AGC Inc, JSR Corporation, Shenzhen Hepalink Pharmaceutical Co Ltd, Kemwell Biopharma Pvt Ltd, Bora Pharmaceuticals Co Ltd, Binex Co Ltd, 3P Biopharmaceuticals SLU, Cytovance Biologics

Access The Complete Biologics CDMO Market Report:

https://www.thebusinessresearchcompany.com/report/biologics-cdmo-global-market-report

Which Region Is The Dominant Market In The Biologics CDMO Market?

North America was the largest region in the biologics CDMO market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biologics cdmo market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Biologics CDMO Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=14056&type=smp

Browse Through More Reports Similar to the Global Biologics CDMO Market 2026, By The Business Research Company

Biologics Cdmo Market Report 2026

https://www.thebusinessresearchcompany.com/report/biologics-cdmo-global-market-report

Biologics Testing Market Report 2026

https://www.thebusinessresearchcompany.com/report/biologics-testing-global-market-report

Biologics Contract Development Market Report 2026

https://www.thebusinessresearchcompany.com/report/biologics-contract-development-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Large Will The Biologics CDMO Market Be By 2030 Compared To Its 2026 Market Size?

The biologics CDMO market size has seen rapid expansion in recent years. It is projected to increase from $24.15 billion in 2025 to $27.56 billion in 2026, with a compound annual growth rate (CAGR) of 14.1%. The growth observed in the historic period can be attributed to the rise in biologics research, advancements in cell culture technologies, increasing prevalence of chronic diseases, growth of biosimilar pipelines, and government support for biopharma manufacturing.

The biologics cdmo market size is projected to experience swift expansion over the upcoming years. By 2030, it is anticipated to reach $48.07 billion, demonstrating a compound annual growth rate (CAGR) of 14.9%. Factors contributing to this growth during the forecast period include a significant increase in gene and cell therapy development, the integration of automation and robotics into CDMO operations, an expansion of global biologics production capabilities, greater investment in precision medicine, and an escalating need for economical biologics. Key trends for the forecast period encompass a broadening of biologics CDMO services, an uptake in mammalian cell-based production, an escalation in the outsourcing of gene therapy manufacturing, the implementation of sophisticated bioprocessing methods, and a growing requirement for biosimilars.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=14056&type=smp

What Key Factors Are Affecting The Biologics CDMO Market Demand?

The escalating demand for cell and genetic therapy is projected to fuel the expansion of the biologic CDMO market moving forward. These advanced medical treatments utilize living cells or genetic material to address fundamental disease causes at the cellular or genetic level, offering potential solutions for conditions resistant to conventional pharmaceuticals. The rising demand for cell and gene therapy stems from their capacity to provide innovative treatments by targeting underlying genetic or cellular issues. Biologic CDMOs offer crucial expertise in handling living cells, viral vectors, and genetic material, ensuring the safe and efficient production of these therapies. They also assist biopharmaceutical companies in navigating regulatory requirements and technical challenges, thus facilitating the translation from research to clinical application. For instance, in March 2024, according to IQVIA Holdings Inc., a US-based provider of advanced analytics, technology solutions, and clinical research services for the life sciences and healthcare industries, global spending on cell and gene therapies reached $5.9 billion in 2023, representing a substantial 38% increase from 2022. Therefore, the significant rise in demand for cell and genetic therapy is a key driver for the growth of the biologic CDMO market.

What Are The Key Segment Divisions In The Biologics CDMO Market Segment Structure?

The biologics cdmo market covered in this report is segmented –

1) By Cell Type: Mammalian, Non-Mammalian

2) By Product Type: Biologics, Biosimilars

3) By Service Type: Drug Substance Manufacturing, Drug Product (Fill–Finish) Manufacturing, Process Development, Analytical & Quality Testing Services

Subsegments:

1) By Mammalian: Chinese Hamster Ovary (CHO) Cells, Human Embryonic Kidney (HEK) Cells, Other Mammalian Cells

2) By Non-Mammalian: Yeast Cells, Bacterial Cells, Insect Cells, Other Non-Mammalian Cells

What Emerging Trends Are Seen In The Biologics CDMO Market?

Leading companies operating in the biologics CDMO market are developing advanced technological solutions, such as new cell lines, to improve biopharmaceutical development and manufacturing efficiency and capabilities. This technology generates therapeutic antibodies with enhanced potency, addressing challenges in immunotherapy research and development. For instance, in November 2023, Lonza Group, a Switzerland-based manufacturing company specializing in the pharmaceutical and biotechnology sectors, introduced GS Effex cell lines, engineered to produce antibodies that are 100% free of fucose, a sugar molecule, and exhibit increased potency without sacrificing other performance attributes. This development helps overcome immunotherapy research and development challenges concerning the requirement for antibody therapeutics to boost potency. It stands as a stable, scalable, and productive cell line, offering a solution for therapeutic development from the discovery stage through to commercial manufacturing.

Which Organizations Are Engaged In The Biologics CDMO Market?

Major companies operating in the biologics cdmo market are Lonza Group Ltd, Samsung Biologics Co Ltd, WuXi Biologics Cayman Inc, Catalent Inc, Thermo Fisher Scientific Inc, Boehringer Ingelheim International GmbH, Emergent BioSolutions Inc, Grifols SA, AbbVie Inc, Novartis AG, Sandoz International GmbH, Fujifilm Holdings Corporation, AGC Inc, JSR Corporation, Shenzhen Hepalink Pharmaceutical Co Ltd, Kemwell Biopharma Pvt Ltd, Bora Pharmaceuticals Co Ltd, Binex Co Ltd, 3P Biopharmaceuticals SLU, Cytovance Biologics

Get The Full Biologics CDMO Market Report:

https://www.thebusinessresearchcompany.com/report/biologics-cdmo-global-market-report

Which Region Dominates The Biologics CDMO Market By Market Share?

North America was the largest region in the biologics CDMO market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biologics cdmo market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Biologics CDMO Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/biologics-cdmo-global-market-report

Browse Through More Reports Similar to the Global Biologics CDMO Market 2026, By The Business Research Company

Biologics Cdmo Market Report 2026

https://www.thebusinessresearchcompany.com/report/biologics-cdmo-global-market-report

Biologics Testing Market Report 2026

https://www.thebusinessresearchcompany.com/report/biologics-testing-global-market-report

Biologics Contract Development Market Report 2026

https://www.thebusinessresearchcompany.com/report/biologics-contract-development-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Value Is Expected For The Biologics CDMO Market At The End Of The 2026–2030 Forecast Period?

The biologics cdmo market size has expanded significantly in recent years. It is projected to grow from $24.15 billion in 2025 to $27.56 billion in 2026, achieving a compound annual growth rate (CAGR) of 14.1%. This historical growth can be attributed to factors such as a rise in biologics research, advancements in cell culture technologies, the increasing prevalence of chronic diseases, the growth of biosimilar pipelines, and government support for biopharma manufacturing.

The biologics cdmo market is projected to expand significantly over the coming years, reaching $48.07 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 14.9%. This anticipated expansion is driven by several factors, including a significant rise in gene and cell therapy development, the integration of automation and robotics within CDMO operations, the broadening of global biologics production capabilities, an uplift in precision medicine investments, and an escalating need for economical biologics. Key developments anticipated during this timeframe involve the broadening of biologics cdmo service offerings, an increase in mammalian cell-based manufacturing, a greater reliance on outsourcing for gene therapy production, the implementation of sophisticated bioprocessing methods, and an elevated call for biosimilars.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=14056&type=smp

What Primary Drivers Are Shaping The Development Of The Biologics CDMO Market?

The growing requirement for cell and genetic therapy is anticipated to boost the expansion of the biologic CDMO market. These therapies represent cutting-edge medical strategies employing living cells or genetic material to target fundamental disease causes at the cellular or genetic level, offering potential cures for conditions otherwise challenging or impossible to treat with conventional drugs. The increasing interest in cell and gene therapy stems from their capacity to provide novel treatments by addressing underlying genetic or cellular issues. Biologic CDMOs offer specialized knowledge in managing living cells, viral vectors, and genetic material, ensuring the secure and effective manufacture of cell and gene therapies. They also support biopharmaceutical firms in overcoming regulatory hurdles and technical complexities, thereby enabling the transition from research to clinical use. For example, in March 2024, IQVIA Holdings Inc., a US-based provider of advanced analytics, technology solutions, and clinical research services for the life sciences and healthcare industries, reported that global expenditure on cell and gene therapies reached $5.9 billion in 2023, marking a 38% rise from 2022. Consequently, the escalating demand for cell and genetic therapy is fueling the expansion of the biologic CDMO market.

What Segment Types Make Up The Biologics CDMO Market?

The biologics cdmo market covered in this report is segmented –

1) By Cell Type: Mammalian, Non-Mammalian

2) By Product Type: Biologics, Biosimilars

3) By Service Type: Drug Substance Manufacturing, Drug Product (Fill–Finish) Manufacturing, Process Development, Analytical & Quality Testing Services

Subsegments:

1) By Mammalian: Chinese Hamster Ovary (CHO) Cells, Human Embryonic Kidney (HEK) Cells, Other Mammalian Cells

2) By Non-Mammalian: Yeast Cells, Bacterial Cells, Insect Cells, Other Non-Mammalian Cells

Which Market Trends Are Creating New Opportunities In The Biologics CDMO Market?

Leading companies operating in the biologics CDMO market are actively developing technologically advanced solutions, such as novel cell lines, to significantly enhance the efficiency and capabilities of biopharmaceutical development and manufacturing. This technology is instrumental in producing therapeutic antibodies with elevated potency, effectively addressing challenges encountered in immunotherapy research and development. For example, in November 2023, Lonza Group, a Switzerland-based manufacturing company focused on the pharmaceutical and biotechnology sectors, introduced its GS Effex cell lines. These lines are specifically engineered to produce antibodies that are 100% free of fucose, a particular sugar molecule, and exhibit increased potency without detriment to other performance characteristics. This development helps to overcome immunotherapy research and development hurdles concerning the requirement for more potent antibody therapeutics. The solution provided is a stable, scalable, and highly productive cell line, offering a complete pathway for therapeutic development, from initial discovery-stage research through to commercial-scale manufacturing.

Who Are The Key Players Driving Competition In The Biologics CDMO Market?

Major companies operating in the biologics cdmo market are Lonza Group Ltd, Samsung Biologics Co Ltd, WuXi Biologics Cayman Inc, Catalent Inc, Thermo Fisher Scientific Inc, Boehringer Ingelheim International GmbH, Emergent BioSolutions Inc, Grifols SA, AbbVie Inc, Novartis AG, Sandoz International GmbH, Fujifilm Holdings Corporation, AGC Inc, JSR Corporation, Shenzhen Hepalink Pharmaceutical Co Ltd, Kemwell Biopharma Pvt Ltd, Bora Pharmaceuticals Co Ltd, Binex Co Ltd, 3P Biopharmaceuticals SLU, Cytovance Biologics

Read the full biologics cdmo market report here:

https://www.thebusinessresearchcompany.com/report/biologics-cdmo-global-market-report

How Does The Biologics CDMO Market Perform Across Major Global Regions?

North America was the largest region in the biologics CDMO market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biologics cdmo market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Biologics CDMO Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=14056&type=smp

Browse Through More Reports Similar to the Global Biologics CDMO Market 2026, By The Business Research Company

Biologics Cdmo Market Report 2026

https://www.thebusinessresearchcompany.com/report/biologics-cdmo-global-market-report

Biologics Testing Market Report 2026

https://www.thebusinessresearchcompany.com/report/biologics-testing-global-market-report

Biologics Contract Development Market Report 2026

https://www.thebusinessresearchcompany.com/report/biologics-contract-development-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the biologics cdmo market from 2026–2035 with trusted insights from The Business Research Company

What is the estimated market size of the Biologics CDMO Market by the end of 2030?

The biologics cdmo market has experienced rapid expansion over recent years. Its projected growth is from $24.15 billion in 2025 to $27.56 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 14.1%. This historical growth has been driven by factors such as the increasing biologics research, innovations in cell culture technologies, the rising incidence of chronic diseases, the expansion of biosimilar pipelines, and government backing for biopharma manufacturing.

The biologics cdmo market is anticipated to show significant expansion in the next few years. It is projected to achieve a value of $48.07 billion by 2030, growing at a compound annual growth rate (CAGR) of 14.9%. This expansion during the forecast period is driven by various factors such as a rise in gene and cell therapy development, the integration of automation and robotics into CDMO processes, an increase in global biologics manufacturing capacity, greater investment in precision medicine, and the increasing need for cost-effective biologics. Prominent trends for the forecast period include the broadening of biologics cdmo services, increased mammalian cell-based production, a rise in the outsourcing of gene therapy manufacturing, the implementation of advanced bioprocessing techniques, and the growing demand for biosimilars.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=14056&type=smp

What Drivers Are Shaping Future Opportunities In The Biologics CDMO Market?

The escalating demand for cell and genetic therapy is projected to fuel the expansion of the biologic CDMO market moving forward. These therapies represent innovative medical approaches that utilize living cells or genetic material to address the root causes of diseases at a cellular or genetic level, potentially treating conditions that are challenging to manage or currently incurable with traditional pharmaceuticals. The demand for cell and gene therapy is increasing due to their promise in offering groundbreaking treatments for diseases by targeting their underlying genetic or cellular origins. Biologic CDMOs provide crucial expertise in handling living cells, viral vectors, and genetic material, which facilitates the safe and efficient production of cell and gene therapies. They also assist biopharmaceutical companies in navigating complex regulatory requirements and technical challenges, thereby streamlining the translation from research to clinical application. For example, in March 2024, as reported by the IQVIA Holdings Inc., a US-based provider of advanced analytics, technology solutions, and clinical research services for the life sciences and healthcare industries, global spending on cell and gene therapies surged to $5.9 billion in 2023, reflecting an increase of 38% from 2022. Thus, the significant rise in demand for cell and genetic therapy is a primary driver behind the growth of the biologic CDMO market.

Which Segments Are Gaining Traction In The Biologics CDMO Market?

The biologics cdmo market covered in this report is segmented –

1) By Cell Type: Mammalian, Non-Mammalian

2) By Product Type: Biologics, Biosimilars

3) By Service Type: Drug Substance Manufacturing, Drug Product (Fill–Finish) Manufacturing, Process Development, Analytical & Quality Testing Services

Subsegments:

1) By Mammalian: Chinese Hamster Ovary (CHO) Cells, Human Embryonic Kidney (HEK) Cells, Other Mammalian Cells

2) By Non-Mammalian: Yeast Cells, Bacterial Cells, Insect Cells, Other Non-Mammalian Cells

What Trends Are Reshaping The Dynamics Of The Biologics CDMO Market?

Leading companies active in the biologics CDMO market are creating advanced technological solutions, such as new cell lines, to improve biopharmaceutical development and manufacturing effectiveness and capacities. This technology generates therapeutic antibodies with enhanced potency, addressing obstacles in immunotherapy research and development. For instance, in November 2023, Lonza Group, a Switzerland-based manufacturing entity focused on the pharmaceutical and biotechnology sectors, launched GS Effex cell lines. These are designed to produce antibodies that are 100% free of fucose, a sugar molecule, and demonstrate increased potency without sacrificing other performance attributes. This innovation helps resolve immunotherapy research and development challenges related to the demand for more potent antibody therapeutics. It is a stable, scalable, and productive cell line that provides a solution for therapeutic development from the initial discovery stage through to commercial manufacturing.

Who Are The Major Companies Operating In The Biologics CDMO Market?

Major companies operating in the biologics cdmo market are Lonza Group Ltd, Samsung Biologics Co Ltd, WuXi Biologics Cayman Inc, Catalent Inc, Thermo Fisher Scientific Inc, Boehringer Ingelheim International GmbH, Emergent BioSolutions Inc, Grifols SA, AbbVie Inc, Novartis AG, Sandoz International GmbH, Fujifilm Holdings Corporation, AGC Inc, JSR Corporation, Shenzhen Hepalink Pharmaceutical Co Ltd, Kemwell Biopharma Pvt Ltd, Bora Pharmaceuticals Co Ltd, Binex Co Ltd, 3P Biopharmaceuticals SLU, Cytovance Biologics

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/biologics-cdmo-global-market-report

Which Region Is Anticipated To See The Fastest Growth In The Biologics CDMO Market?

North America was the largest region in the biologics CDMO market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biologics cdmo market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Biologics CDMO Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=14056&type=smp

Browse Through More Reports Similar to the Global Biologics CDMO Market 2026, By The Business Research Company

Biologics Cdmo Market Report 2026

https://www.thebusinessresearchcompany.com/report/biologics-cdmo-global-market-report

Biologics Testing Market Report 2026

https://www.thebusinessresearchcompany.com/report/biologics-testing-global-market-report

Biologics Contract Development Market Report 2026

https://www.thebusinessresearchcompany.com/report/biologics-contract-development-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the biologics cdmo market from 2025–2034 with trusted insights from The Business Research Company

What Is The Projected Valuation Of The Biologics CDMO Market In The Period 2029-2034?

The biologics CDMO market has experienced rapid expansion in recent years. It is projected to grow from $21.3 billion in 2024 to $24.15 billion in 2025, at a compound annual growth rate (CAGR) of 13.4%. The historical growth can be attributed to factors such as the rise in biologics development, enhanced cost efficiency and flexibility, a focus on core competencies, adherence to regulatory compliance and quality assurance, and the globalization of pharmaceutical supply chains.

The biologics CDMO market is projected for significant expansion in the coming years. This market is anticipated to reach a valuation of $41.53 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 14.5%. Factors driving this growth during the forecast period include a rising need for biologic treatments, the advent of biosimilars and biobetters, increased capital into biomanufacturing infrastructure, a move towards externalizing intricate processes, an emphasis on robust supply chains and risk mitigation, streamlined regulations, and faster approval pathways. Key developments expected in this period encompass broadening service offerings to provide comprehensive solutions, the widespread use of single-use technologies, incorporating continuous manufacturing methods, and the rise of highly specialized CDMOs.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=14056&type=smp

What Strategic Drivers Are Accelerating The Biologics CDMO Market Expansion?

The rising need for cell and genetic therapy is anticipated to fuel the expansion of the biologic CDMO market moving forward. These therapies represent advanced medical strategies that use living cells or genetic material to address the fundamental causes of diseases at a cellular or genetic level, potentially offering treatments for conditions that are difficult to manage or incurable with traditional pharmaceuticals. The increasing demand for cell and gene therapy is attributed to their potential to provide innovative disease treatments by targeting underlying genetic or cellular issues. Biologic CDMOs provide specialized expertise in handling living cells, viral vectors, and genetic material, which enables the safe and efficient production of cell and gene therapies. They also assist biopharmaceutical companies in navigating regulatory requirements and technical challenges, thereby facilitating the transition from research to clinical application. For instance, in January 2023, The American Society of Gene & Cell Therapy (ASGCT), a US-based primary professional membership organization, reported that the gene, cell, and RNA therapy pipeline experienced 7% growth in 2022, accumulating a total of 3,726 therapies in development. Among these, 55% are gene therapies, 22% are non-genetically modified cell therapies, and 23% are RNA therapies. Thus, the escalating demand for cell and genetic therapy is a key factor propelling the growth of the biologic CDMO market.

What Is The Detailed Segment Distribution Of The Biologics CDMO Market?

The biologics cdmo market covered in this report is segmented –

1) By Cell Type: Mammalian, Non-Mammalian

2) By Product Type: Biologics, Biosimilars

Subsegments:

1) By Mammalian: Chinese Hamster Ovary (CHO) Cells, Human Embryonic Kidney (HEK) Cells, Other Mammalian Cells

2) By Non-Mammalian: Yeast Cells, Bacterial Cells, Insect Cells, Other Non-Mammalian Cells

How Are Global Trends Impacting The Development Of The Biologics CDMO Market?

Major companies operating in the biologics CDMO market are developing technologically advanced solutions, such as new cell lines, to enhance biopharmaceutical development and manufacturing efficiency and capabilities. This technology generates therapeutic antibodies with improved potency, addressing challenges in immunotherapy research and development. For instance, in November 2023, Lonza Group, a Switzerland-based manufacturing company specializing in the pharmaceutical and biotechnology sectors, launched GS Effex cell lines. These lines are designed to produce antibodies that are 100% free of fucose, a sugar molecule, and demonstrate increased potency without compromising other performance attributes. This innovation helps overcome immunotherapy research and development challenges concerning the need for more potent antibody therapeutics. The cell line is stable, scalable, and productive, providing a comprehensive solution for therapeutic development from discovery-stage research through commercial manufacturing.

Who Are The Major Stakeholders Operating In The Biologics CDMO Market?

Major companies operating in the biologics CDMO market are AbbVie Inc., Thermo Fisher Scientific Inc., Novartis AG, Evonik Industries AG, Sandoz International GmbH, ICON PLC, Grifols SA, Lonza Group Ltd., Boehringer Ingelheim International GmbH, Catalent Inc., JSR Corp., Parexel International Corporation, WuXi Biologics (Cayman) Inc., Samsung Biologics Co. Ltd., Emergent BioSolutions Inc., Rentschler Biopharma SE, FUJIFILM Diosynth Biotechnologies U.S.A. Inc., Binex Co. Ltd., Bora Pharmaceuticals Co. Ltd, 3P Biopharmaceuticals s.l.u, JRS Pharma LP, J Rettenmaier and SOHNE GmbH and Co KG, Kemwell Biopharma Pvt. Ltd., Cytovance Biologics, AGC Biologics, Shenzhen Hepalink Pharmaceutical Co. Ltd.

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/biologics-cdmo-global-market-report

Which Region Is Projected To Achieve The Fastest Growth In The Biologics CDMO Market?

North America was the largest region in the biologics CDMO market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biologics CDMO market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=14056&type=smp

Browse Through More Reports Similar to the Global Biologics CDMO Market 2025, By The Business Research Company

Biodegradable Plastics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/biodegradable-plastics-global-market-report

Soap And Other Detergents Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/soap-and-other-detergents-global-market-report

Detergent Chemicals Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/detergent-chemicals-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Are The Forecasted Market Size Estimates For The Biologics CDMO Market Between 2025 And 2029?

The biologics CDMO market has experienced substantial expansion in recent years. Its value is projected to rise from $21.3 billion in 2024 to $24.15 billion in 2025, achieving a compound annual growth rate (CAGR) of 13.4%. The factors contributing to its historical growth include an increase in biologics development, the advantages of cost efficiency and flexibility, an emphasis on core competencies, adherence to regulatory compliance and quality assurance, and the globalization of pharmaceutical supply chains.

The biologics CDMO market size is anticipated to expand significantly in the coming years, reaching $41.53 billion by 2029, with a compound annual growth rate (CAGR) of 14.5%. This growth during the forecast period is driven by factors such as the increasing demand for biologic therapies, the introduction of biosimilars and biobetters, greater investments in biomanufacturing infrastructure, a shift towards outsourcing complex processes, a strong focus on supply chain resilience and risk mitigation, regulatory harmonization, and expedited approvals. Key trends expected in the forecast period involve expanding capabilities to offer comprehensive end-to-end solutions, the adoption of single-use technologies, the integration of continuous manufacturing processes, and the emergence of specialized CDMOs.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=14056&type=smp

Which Drivers Are Supporting Growth Of The Biologics CDMO Market?

The increasing need for cell and genetic therapy is anticipated to boost the expansion of the biologic CDMO market in the future. These therapies represent cutting-edge medical methods that employ live cells or genetic material to target fundamental disease origins at a cellular or genetic scale, offering prospective solutions for illnesses resistant to conventional drugs or deemed incurable. The growing interest in cell and gene therapy stems from their capacity to provide novel disease treatments by tackling core genetic or cellular issues. Biologic CDMOs offer specialized knowledge in managing live cells, viral vectors, and genetic material, ensuring the secure and effective manufacturing of cell and gene therapies. They also support biopharmaceutical firms through regulatory complexities and technical hurdles, thus accelerating the transition from laboratory research to clinical implementation. As an illustration, The American Society of Gene & Cell Therapy (ASGCT), a leading US professional body, reported in January 2023 that the pipeline for gene, cell, and RNA therapy expanded by 7% in 2022, accumulating 3,726 therapies under development. Among these, 55% were gene therapies, 22% were non-genetically modified cell therapies, and 23% were RNA therapies. Consequently, the increased demand for cell and genetic therapy is a key factor propelling the expansion of the biologic CDMO market.

What Are The Different Segment Classifications Within The Biologics CDMO Market?

The biologics cdmo market covered in this report is segmented –

1) By Cell Type: Mammalian, Non-Mammalian

2) By Product Type: Biologics, Biosimilars

Subsegments:

1) By Mammalian: Chinese Hamster Ovary (CHO) Cells, Human Embryonic Kidney (HEK) Cells, Other Mammalian Cells

2) By Non-Mammalian: Yeast Cells, Bacterial Cells, Insect Cells, Other Non-Mammalian Cells

How Are Trends Influencing The Biologics CDMO Market?

Leading companies in the biologics CDMO market are developing advanced technological solutions, such as new cell lines, to enhance the efficiency and capabilities of biopharmaceutical development and manufacturing. This technology produces therapeutic antibodies with improved potency, addressing challenges in immunotherapy research and development. For instance, in November 2023, Lonza Group, a Switzerland-based manufacturing company specializing in the pharmaceutical and biotechnology sectors, launched GS Effex cell lines. These are designed to produce antibodies that are 100% free of fucose, a sugar molecule, and demonstrate increased potency without compromising other performance attributes. This innovation helps overcome immunotherapy research and development challenges related to the necessity for antibody therapeutics to enhance potency. It represents a stable, scalable, and productive cell line, offering a solution for therapeutic development from discovery-stage research through to commercial manufacturing.

Which Key Market Players Are Investing In Expansion And Innovation Of Biologics CDMO Market?

Major companies operating in the biologics CDMO market are AbbVie Inc., Thermo Fisher Scientific Inc., Novartis AG, Evonik Industries AG, Sandoz International GmbH, ICON PLC, Grifols SA, Lonza Group Ltd., Boehringer Ingelheim International GmbH, Catalent Inc., JSR Corp., Parexel International Corporation, WuXi Biologics (Cayman) Inc., Samsung Biologics Co. Ltd., Emergent BioSolutions Inc., Rentschler Biopharma SE, FUJIFILM Diosynth Biotechnologies U.S.A. Inc., Binex Co. Ltd., Bora Pharmaceuticals Co. Ltd, 3P Biopharmaceuticals s.l.u, JRS Pharma LP, J Rettenmaier and SOHNE GmbH and Co KG, Kemwell Biopharma Pvt. Ltd., Cytovance Biologics, AGC Biologics, Shenzhen Hepalink Pharmaceutical Co. Ltd.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/biologics-cdmo-global-market-report

Which Geographies Are Emerging As Strong Markets For The Biologics CDMO Industry?

North America was the largest region in the biologics CDMO market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biologics CDMO market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Biologics CDMO Market Report:

https://www.thebusinessresearchcompany.com/customise?id=14056&type=smp

Browse Through More Reports Similar to the Global Biologics CDMO Market 2025, By The Business Research Company

Biodegradable Plastics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/biodegradable-plastics-global-market-report

Soap And Other Detergents Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/soap-and-other-detergents-global-market-report

Detergent Chemicals Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/detergent-chemicals-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Are the Latest Market Insights for the Biologics CDMO Industry?

The advancement in the biologics CDMO market has been quite swift in the past few years. The market size is projected to escalate from $21.3 billion in 2024 to $24.15 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 13.4%. The growth witnessed in the historic period is influenced by factors such as the emergence of biologics development, cost efficiency and adaptability, emphasis on core competencies, assurance of regulatory compliance and quality, and the global expansion of pharmaceutical supply chains.

The market size of the biologics CDMO is anticipated to witness expedited growth in the upcoming years, expanding to “$41.53 billion in 2029” with a compound annual growth rate (CAGR) of “14.5%”. Multiple factors will contribute to this growth pattern in the predicted timeframe, including the growing need for biologic therapies, the rise of biosimilars and biobetters, investments flowing into biomanufacturing infrastructure, the move towards outsourcing intricate processes, emphasis on maintaining resilience in the supply chain and mitigating risks, regulatory harmonization, and fast-tracked approvals. Notable trends over the forecast period comprise expansion of capabilities to deliver comprehensive solutions, the incorporation of single-use technologies, the inclusion of continuous manufacturing processes, and the emergence of specialized CDMOs.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=14056&type=smp

What Forces Are Driving The Growth Of The Biologics CDMO Industry?

The biologic CDMO market is anticipated to grow due to the increasing demand for cell and genetic therapy. These innovative medical strategies use living cells or genetic material to address disease causes at the cellular or genetic level. They provide potential remedies for conditions otherwise difficult to treat or cure with conventional medications. The rising demand for these therapies is attributed to their groundbreaking approach in disease treatment, tackling underlying genetic or cellular causes. Biologic CDMOs offer expertise in dealing with living cells, viral vectors, and genetic material. They promote safe and effective production of cell and gene therapies and assist biopharmaceutical companies in meeting regulatory standards and technical obstacles, hence promoting the transition from research to clinical application. For example, The American Society of Gene & Cell Therapy (ASGCT), a top professional membership organization based in the U.S., reported in January 2023 that the gene, cell, and RNA therapy pipeline experienced a 7% growth in 2022, reaching a total of 3,726 therapies under development. Among these, 55% are gene therapies, 22% are non-genetically modified cell therapies, and 23% are RNA therapies. Thus, the rising demand for cell and genetic therapy is fueling the growth of the biologic CDMO market.

The biologics cdmo market covered in this report is segmented –

1) By Cell Type: Mammalian, Non-Mammalian

2) By Product Type: Biologics, Biosimilars

Subsegments:

1) By Mammalian: Chinese Hamster Ovary (CHO) Cells, Human Embryonic Kidney (HEK) Cells, Other Mammalian Cells

2) By Non-Mammalian: Yeast Cells, Bacterial Cells, Insect Cells, Other Non-Mammalian Cells

How Are Key Trends Driving Expansion In The Biologics CDMO Industry?

Leading entities in the biologics CDMO industry are engineering technologically superior solutions, including novel cell lines, to bolster the efficacy and capabilities of biopharmaceutical development and manufacturing. This innovation leads to the creation of more potent therapeutic antibodies, thereby resolving issues faced in R&D for immunotherapy. For example, Lonza Group, a Swiss manufacturing corporation renowned in the pharma and biotech fields, unveiled their GS Effex cell lines in November 2023. These are intended for generating antibodies that are entirely devoid of fucose, a type of sugar molecule, and exhibit boosted potency without sacrificing other performance factors. This initiative aids in tackling problems associated with augmenting the potency of antibody therapeutics in immunotherapy R&D. The GS Effex cell lines are stable and scalable, offering a viable approach for therapeutic advancement that serves processes from discovery-stage investigation to commercial-scale manufacturing.

Who Are The Primary Players Operating Across The Global Biologics CDMO Market?

Major companies operating in the biologics CDMO market are AbbVie Inc., Thermo Fisher Scientific Inc., Novartis AG, Evonik Industries AG, Sandoz International GmbH, ICON PLC, Grifols SA, Lonza Group Ltd., Boehringer Ingelheim International GmbH, Catalent Inc., JSR Corp., Parexel International Corporation, WuXi Biologics (Cayman) Inc., Samsung Biologics Co. Ltd., Emergent BioSolutions Inc., Rentschler Biopharma SE, FUJIFILM Diosynth Biotechnologies U.S.A. Inc., Binex Co. Ltd., Bora Pharmaceuticals Co. Ltd, 3P Biopharmaceuticals s.l.u, JRS Pharma LP, J Rettenmaier and SOHNE GmbH and Co KG, Kemwell Biopharma Pvt. Ltd., Cytovance Biologics, AGC Biologics, Shenzhen Hepalink Pharmaceutical Co. Ltd.

https://www.thebusinessresearchcompany.com/report/biologics-cdmo-global-market-report

Which Region Offers The Most Growth Potential For The Biologics CDMO Market Through 2029?

North America was the largest region in the biologics CDMO market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biologics CDMO market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=14056&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model